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Abstract. Background: The potential mechanism of malignant
transformation from leiomyoma to leiomyosarcoma is still
debated. The aim was the evaluation of expression patterns of
mucin-1 (MUC1) (MUC1 VU-4-H5), galectin-1 (Gal-1) and
galectin-3 (Gal-3) in human myometrium and leiomyoma and
in comparison to leiomyosarcoma. Materials and Methods:
Myometrium, leiomyoma and leiomyosarcoma tissues were
obtained from 79 patients. Samples were analyzed regarding the
expression of MUC1, Gal-1 and Gal-3 by immunohistochemical
staining of paraffin-embedded material. Results: The expression
of MUC1 (VU4-H5) was up-regulated in leiomyoma (p=0.065)
and leiomyosarcoma (p=0.039) as compared to the
myometrium. In contrast, there were no significant differences in
expression of Gal-3 in the tissues from the myometrium, myoma
and leiomyosarcoma. Concerning Gal-1 expression, the
differences were not significant comparing myometrium and
leiomyosarcoma (p=0.277). Myoma had elevated levels of Gal-
1 compared to myometrium (p=0.007) and leiomyosarcoma
(p<0.0001). Conclusion: MUC1 and Gal-1 might be useful for
evaluating the potential of leiomyoma to transform into
leiomyosarcoma and, therefore, help in risk-adapted
consultation and adjusted treatment. 
Uterine leiomyomas are the most common pelvic tumour of
women of reproductive age (1, 2). They are the major cause
of hysterectomy in the United states (1). Differences occur
by race and age, and black women have a greater burden
compared to white women regarding fibroids and their
symptoms (3-5). It is still not known if leiomyosarcomas can
arise from pre-existing leiomyomas or if they develop de
novo (6). Malignant transformation of leiomyoma into
leiomyosarcoma is still debated in the literature and several
studies have focused on that topic (6-8). 
Mittal et al. demonstrated, that leiomyosarcomas can arise
from leiomyoma-like areas (9). Histopathological
characterization is often challenging and differentiation
between leiomyoma, myoma with pseudosarcomatous features
and leiomyosarcoma can be exceedingly difficult (10). 
Epithelial mucin-1 (MUC1) is a complex glycoprotein.
The mature molecule is anchored within the cell surface by
transmembrane proteins, however, most of the mucin is
expressed extracellularly (11). Numerous functions are
proposed for MUC1. It has a potential role in tumour
progression and metastasis by changing expression in the
basolateral front. Antiadhesive effects in tumour cells seem
to be mediated by MUC1. Furthermore, it is responsible for
surveillance by the host immune response. Mucin-expressing
cells have been demonstrated to be generally resistant to
natural killer cells and cytotoxic T-cells (12). In addition,
MUC1 is associated with tyrosine kinase receptor activity
and is involved in cell transduction processes (13). Price et
al. (11) mapped 56 monoclonal reactive antibodies against
MUC1 mucin. Regarding the specificity of the antibody
clone VU-4-H5 the core reactivity is ambiguous (14). 
The overexpression of MUC1 and its relationship to several
types of cancer has already been demonstrated (15). The
clones DF3 (CA15-3), VU-4-H5 and Panko-Mab of MUC1
were examined by Dian et al. and breast cancer. Panko-Mab
showed significant differences in staining in breast cancer
patients with oestrogen negative carcinomas compared to
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positive carcinomas. While the DF3 staining results were not
significant, for the VU-4-H5 antibody, a significant correlation
with lymph node involvement and grading, (staining increased
from G1 to G3 carcinomas) was found (16). 
Galectin-1 (Gal-1) belongs to the family of carbohydrate-
binding proteins, with affinity for beta-galactosides. Similar
to MUC1, both intracellular and extracellular activity is
described and the biological activity has a wide range. Gal-
1 regulates immune responses such as T-cell homeostasis and
survival, T-cell immune disorders, inflammation and
allergies, as well as host–pathogen interactions (17), and is
also a mediator in malignant tumour progression (18). 
Galectin-3 (Gal-3), like Gal-1, belongs to the family of
beta-galactoside-binding proteins (19). Additionally, Gal-3
binds to the Thomsen-Friedenreich (TF) antigen (Galbeta1-
3GalNAc), which has been demonstrated to be the
glycosylated form of MUC1 (20-22). Biological regulation,
such as cell adhesion, cell growth, apoptosis, tumour
progression and metastatic potential, is attributed to Gal-3.
Up-regulated expression of Gal-3 is associated with tumour
progression and neoplastic potential. The inhibition of
apoptosis by Gal-3 seems to be related to an inhibition of
cytochrome c release and caspase activation (23, 24). 
Galectins influence immune and inflammatory responses
and as a consequence facilitate tumour subversion of
immune surveillance. Recent studies have focused on
galectins and demonstrated their important role in neoplastic
transformations and tumour progression (25). 
The aim of this study was to evaluate any individual
differences in staining of these glycoproteins and, as a
consequence, variation in the potential of leiomyomas to
transform malignantly. Accordingly, the expression of MUC1
(VU-4-H5), Gal-1 and Gal-3 was examined immunohisto-
chemically in human myometrium, in uterine myoma and in
leiomyosarcoma. 
Materials and Methods
All the study subjects had complaints due to uterine myomas, mainly
dysmenorrhoea, menorrhagia, metrorrhagia, hypermenorrhoea,
pollacisuria and/or painful pressure in the abdomen and were
attending consultations in the Department of Obstetrics and
Gynecology in the University Hospital, Munich. All the patients were
interviewed regarding history of myomas, pregnancies, modality of
birth and past or present hormone use. Patients who could not give
informed consent were excluded. To avoid ambiguous results due to
differences of uterine malignancies, leiomyosarcomas were focused
upon and other histological types, such as adenocarcinomas, were
excluded. Forty-four women with uterine myomas and 35 with
leiomyosarcomas were included in the study. The Institutional Review
Board of the Ludwig Maximilians University Munich, Germany,
approved the study and all the patients gave informed consent.
The 44 uterine myoma patients received endoscopic myomectomia
and the 35 leiomyosarcoma patients received hysterectomy and further
oncological surgery according to age and extension of disease. Two
tissue samples from each myoma were examined, totalling 88 samples
for immunhistochemical investigation and within the myomectomia,
30 myometrial tissues were taken and also investigated. 
The immunohistochemistry was performed using a combination of
pressure cooker heating and the standard streptavidin-biotin-
peroxidase complex using the mouse IgG-Vectastain Elite ABC kit
(Vector Laboratories, Burlingame, CA, USA). The mouse monoclonal
antibodies used for these experiments are listed in Table I.
Paraffin-fixed tissue sections were dewaxed using xylol for 15 min,
rehydrated in an descending series of alcohol (100%, 96% and 70%),
and subjected to epitope retrieval for 10 min in a pressure cooker using
sodium citrate buffer (pH 6.0) containing 0.1 M citric acid and 0.1 M
sodium citrate in distilled water. After cooling, the sections were washed
twice in PBS. Endogenous peroxidase activity was quenched by
immersion in 3% hydrogen peroxide (Merck, Darmstadt, Germany) in
methanol for 20 min. Non-specific binding of the primary antibodies
was blocked by incubating the sections with diluted normal serum 
(10 ml PBS containing 150 SI horse serum; Vector Laboratories) for 20
min at room temperature. The sections were then incubated at room
temperature for 60 min with the primary antibodies. After washing with
PBS, the sections were incubated in diluted biotinylated serum (10 ml
PBS containing 50 IL horse serum; Vector Laboratories) for 
30 min at room temperature. After incubation with the avidin-biotin
peroxidase complex (diluted in 10 ml PBS; Vector Laboratories) for 30
min and repeated washing steps with PBS, visualisation was performed
with substrate and the chromagen 3,3’-diaminobenzidine (DAB; Dako,
Glostrup, Denmark) for 8-10 min. The sections were counterstained with
Mayer‘s acidic haematoxylin and dehydrated in an ascending series of
alcohol (50-98%). After xylol treatment, the sections were covered.
Negative controls were performed by replacing the primary antibody
with normal horse serum. Immunohistochemical staining was performed
using an appropriate positive control. Positive cells showed a brownish
colour and negative controls, as well as unstained cells, were blue. 
The intensity and distribution patterns of specific immuno-
histochemical staining were evaluated using the semi-quantitative
International Remmele Score (IRS), as described elsewhere, to assess
the expression pattern of other molecules, such as steroid receptors,
glycodelin and MUC1 (26-28). The IRS score was calculated by
multiplication of the optical staining intensity (graded as 0=no,
1=weak, 2=moderate and 3=strong staining) and the percentage of
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Table I. Antibodies used in the study.
Antibody Clone Isotype Concentration Source
Galectin-1 AF1152 Goat IgG 1.4 μg/ml R&D Systems, Wiesbaden, Germany
Galectin-3 9C4 Mouse IgG 2.0 μg/ml Novocastra, Wetzlar, Germany
Mucin-1 VU-4-H5 Mouse IgG1 6.8 μg/ml Zymed, San Francisco, USA
positively stained cells (0=no staining, 1=<10% of cells, 2=11-50%
of cells, 3=51-80% of cells and 4= >81% of cells stained). The slides
were examined by two independent observers. Sections were
examined using a charge coupled device (CCD) colour camera with a
special prism block to separate the colors and three CCDs for the red,
green and blue color planes (JVC, Victor Company of Japan,
Yokohama, Japan) and a Leitz (Wetzlar, Germany) microscope. The
results were evaluated using the non-parametric Mann-Whitney U
test, and the non-parametric Spearman correlation coefficient was
used for estimating correlations between MUC1, Gal-3, and Gal-1
(SPSS; Chigaco, IL, USA). Significance was assumed at p<0.05.
Results
MUC1 (VU-4-H5). In the myometrial tissue samples, as
expected, no expression of MUC1 (VU-4-H5) was
demonstrated (Figure 1). The leiomyosarcomas (Figure 1e,
f) showed significantly higher MUC1 expression compared
to the myometria (Figure 1a,1b p=0.039). The myomas
(Figure 1c, d) revealed up-regulated MUC1 expression
compared to the myometria. However, this result was not
significant (p=0.065). MUC1 expression was high in both
leiomyosarcomas and myomas, but the differences were not
significant (p=0.418). A quantitative summary of the staining
results is presented in Figure 1g. 
Gal-3. There were no significant differences when
comparing all three groups for Gal-3 tissue expression, as
demonstrated in Figure 2a-f. A quantitative summary of this
staining result is presented in Figure 2g.
Gal-1. Gal-1 demonstrated significantly lower immunohisto-
chemical staining in tissues of the leiomyosarcomas (Figure
3e, f) compared to the myomas (Figure 3c, d) (p<0.0001).
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Figure 1. MUC1 (VU-4-H5) expression in myometrium (a, b), myoma (c, d) and leiomyosarcoma (e, f); magnification ×10 (a, c, e) and ×40 (b, d,
f). Semiquantitative evaluation of staining results (IRS score) is presented in box plots (g). The boxes represent the range between the 25th and 75th
percentiles, with a horizontal line at the median. The bars deliniate the 5th and 95th percentiles. The circles indicate values more than 1.5 box
lengths from the 75th percentile.
Similar to this result, the myometria (Figure 3a, b) also
showed lower staining compared to the myomas (p=0.007).
No significant differences in staining between the myometria
and the leiomyosarcomas was found (p=0.277). A quantitative
summary of this staining result is presented in Figure 3g.
Discussion
PEP-19, a neurone-specific protein PEP-19 (Purkinje cell
protein) seems to be involved in the pathogenesis of
leiomyoma. PEP-19 expression was investigated for a series
of human leiomyoma, as well as normal myometrium and
leiomyosarcoma, and was demonstrated to be involved in
leiomyoma pathogenesis (2).
Additionally, angiogenetic factors, such as vascular
endothelial growth factor (VEGF) and the expression of the
VEGF receptors, EGF-R and Ki-67 were investigated in
leiomyomas and leiomyosarcomas (29, 30). Accordingly,
angiogenic growth factors seem to play an important role in
the induction of malignant transformation of
leiomyosarcomas. 
Fascin, an actin bundling protein was recently described
to be related to gastric carcinoma (31) and even breast cancer
(31, 32). This protein regulates cytoskeletal structures and
maintains cell adhesion. In 2009, Kefeli et al. described
elevated fascin expression in leiomyosarcoma compared to
leiomyoma, leiomyoma variants and uterine smooth muscle
tumour of uncertain malignant potential (33). Possibly,
varied mechanisms of cell adhesion might have been
implicated in development of leiomyosarcoma. 
In the present study, MUC1 expression was up-regulated
in leiomyosarcoma and also in leiomyoma compared to the
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Figure 2. Gal-3 expression in myometrium (a, b), myoma (c, d) and leiomyosarcoma (e, f); magnification ×10 (a, c, e) and ×40 (b, d, f).
Semiquantitative evaluation of staining results (IRS score) is presented in box plots (g). The boxes represent the range between the 25th and 75th
percentiles with a horizontal line at the median. The bars deliniate the 5th and 95th percentiles. The circles indicate values more than 1.5 box
lengths from the 75th percentile.
myometrium samples. Myometrial expression of MUC1 was
negative with a few exceptions due to the nature of MUC1 as
a glandular marker. Interestingly, only VU-4-H5 out of three
anti-MUC1 (16) antibodies tested (PankoMab and DF3)
showed positive staining in this tissue. Mylonas et al. also
found up-regulated expression of MUC1 in endometrioid
adenocarcinoma (15). However, tissues of leiomyosarcomas
(mesenchymal tumours) and adenocarcinomas (epithelial
tumours) are not comparable regarding MUC1 expression.
MUC1 is also overexpressed in ovarian cancer and MUC1
signalling pathways have been shown by Hu et al. to be
responsible for malignant transformation and metastasis (34).
Particularly for the VU-4-H5 epitope, a correlation of lymph
node involvement and grading and increased staining
intensity has been shown in patients with breast cancer (16).
However, MUC1 expression in leiomyomas compared to
leiomyosarcomas has not previously been investigated. 
VU-4-H5 is directed against the core peptide of MUC1
and stains positively only when the MUC1 molecule is
underglycosylated, presenting simpler and fewer
carbohydrate chains (35). Incomplete glycosylation,
abnormal distribution and ectopic expression of mucins seem
to be characteristics of malignancy (36).
In the present study, Gal-3 expression seemed to be down-
regulated in the patients with leiomyosarcoma, however, not
significantly so when compared to myometrium and to
leiomyoma. Since malignant transformation (25) and tumour
progression, cell growth and apoptosis (23, 24) are regulated
by Gal-3, a correlation of Gal-3 with tumour progression and
metastasis has to be assumed. 
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Figure 3. Gal-1 expression in myometrium (a, b), myoma (c, d) and leiomyosarcoma (e, f); magnification ×10 (a, c, e) and ×40 (b, d, f).
Semiquantitative evaluation of staining results (IRS score) is presented in box plots (g). The boxes represent the range between the 25th and 75th
percentiles with a horizontal line at the median. The bars deliniate the 5th and 95th percentiles. The circles indicate values more than 1.5 box
lengths from the 75th percentile.
Tsuboi et al. found an association between reduced
expression of Gal-3 and invasion and metastasis of colorectal
cancer (37), which was consistent with the present trend in
leiomyosarcoma. Additionally, interactions between Gal-3
and MUC1 seem to play an important role. Recombinant
Gal-3 has been demonstrated to interact with MUC1 via the
Thomsen-Friedenreich antigen (21, 22).  
Strong binding of Gal-1 in stage III/IV endometrioid
adenocarcinomas and an association with lymphangiosis
have been reported (15). The present study found the highest
Gal-1 expression to be in the fibroid tissues and similar
expression patterns in myometrium and leiomyosarcoma, but
adenocarcinomas, which might have different patterns of
galectin expression, were not examined. 
Gal-1 expression has been demonstrated to be related to
tumour progression and must also be considered regarding
dissemination of tumour cells into surrounding normal
tissues and tumour immune escape (17). Such findings were
confirmed by Rabinovich et al. who emphasized galectins as
potential targets of anticancer drugs (18). The present results
did not show any up-regulated Gal-1 expression in the
leiomyosarcomas, on the contrary, Gal-1 expression was
highest in the leiomyomas. 
In conclusion, VU-4-H5 is an anti-MUC1 antibody with
diagnostic potential, showing increasing expression from
myometrium to myoma and leiomyosarcoma. Gal-1
expression might be a potential option in the analysis of
benign epithelial tumours and MUC1(VU-4-H5) in
combination with Gal-1 may be an option for assessing the
potential for malignant transformation of myoma.
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